ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
05 janv. 2023 08h00 HE
|
Shape Therapeutics, Inc.
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare...
EHang Announces Strategic Partnership and Investment with Qingdao West Coast New Area
23 déc. 2022 08h00 HE
|
EHang Holdings Limited
GUANGZHOU, China, Dec. 23, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang Holdings Limited Announces Appointment of Nick Ning Yang as New Independent Director
05 déc. 2022 07h27 HE
|
EHang Holdings Limited
GUANGZHOU, China, Dec. 05, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang to Report Third Quarter 2022 Unaudited Financial Results on Friday, December 2, 2022
21 nov. 2022 07h30 HE
|
EHang Holdings Limited
GUANGZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang and HAECO Group Explore Partnership in Advanced Air Mobility
31 oct. 2022 08h44 HE
|
EHang Holdings Limited
GUANGZHOU, China, Oct. 31, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 oct. 2022 16h01 HE
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory...
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
04 oct. 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...
EHang Announces Progress in EH216-S Type Certification Process as It Enters into More In-Depth Review Phase
30 sept. 2022 10h07 HE
|
EHang Holdings Limited
GUANGZHOU, China, Sept. 30, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform...
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 sept. 2022 17h30 HE
|
Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...
EHang Reports Second Quarter 2022 Unaudited Financial Results
18 août 2022 05h00 HE
|
EHang Holdings Limited
– Total Revenues Up 152.5% QoQ– High Quarterly Gross Margin of 67.1%– Indicative Facilities of RMB1 Billion by Agricultural Bank of China Guangzhou Branch– Increasing Deliveries in China and...